Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296546 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296494 | 0.82 | KDM4E (0.51) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL18344188 | 0.82 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296513 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296662 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296436 | 0.79 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296245 | 0.78 | NPC1 (0.42) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL20296433 | 0.77 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9ATP53MITF | |
| SCHEMBL27644677 | 0.76 | RAB9A (0.58) | SMN1; SMN2NPC1RAB9ATP53GAA | |
| SCHEMBL20296509 | 0.76 | CNR2 (0.46) | SMN1; SMN2NPC1RAB9ATP53MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | SMN1; SMN2 3582/4885NPC1 3120/4885RAB9A 2128/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | SMN1; SMN2 3582/4885NPC1 3120/4885RAB9A 2128/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | SMN1; SMN2 3582/4885NPC1 3120/4885RAB9A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.